EDDING GENOR (06998) announced that on March 3, 2026, the Group entered into a supplementary agreement and a termination agreement with Nataide (Qingdao) Biopharmaceutical Co., Ltd. These agreements pertain to the licensing arrangement between the target group and Nataide concerning certain siRNA assets. In September 2023, the target group signed a licensing agreement with Nataide to obtain exclusive rights for the development, production, and commercialization of two innovative preclinical siRNA assets. This was followed by the licensing of another siRNA asset in May 2024. According to the newly signed agreements, the parties have agreed to the following adjustments to their collaboration: (i) The territorial scope for one of the siRNA assets, targeting Angiopoietin-like protein 3 (ANGPTL3), has been expanded from the originally agreed territory to a global range. Consequently, the Group will acquire global patent rights related to the ANGPTL3 molecule and will co-own the GalNAc platform technology with Nataide; and (ii) The collaboration arrangements for the other two preclinical siRNA assets have been terminated. Following the signing of the supplementary agreement, the licensed territory for the ANGPTL3 siRNA asset has been extended globally, which enhances the asset's value within the company and is conducive to increasing the company's long-term shareholder value. The company's candidate drug for ANGPTL3, EDP167, has successfully administered the first dose to a subject in its Phase II clinical trial. Considering the competitive market environment, the company has terminated the collaboration on the other two preclinical siRNA assets. As the other two siRNA assets are still in the early stages of research and development, the termination of the collaboration concerning these assets is not expected to have any material adverse effect on the Group's business, financial condition, or operations.